A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

Thomas J Kipps, Herbert Aaron Eradat, Sebastian Grosicki, John Catalano, Walter Cosolo, Iryna S Dyagil, Sreeni Yalamanchili, Akiko Chai, Srikumar Sahasranaman, Elizabeth A Punnoose, Deborah Hurst, Halyna Pylypenko

    Research output: Contribution to journalArticleResearchpeer-review

    107 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)2826 - 2833
    Number of pages8
    JournalLeukemia and Lymphoma
    Issue number10
    Publication statusPublished - 2015

    Cite this